Anticoagulant management of atrial fibrillation: the influence of dosing algorithm and recall schedule on time in therapeutic range

被引:1
|
作者
Nantha, Y. Swarna [1 ,2 ]
机构
[1] Seremban Primary Care Clin, Primary Care Res Initiat, Seremban 70300, Negeri Sembilan, Malaysia
[2] Seremban Primary Care Clin, Methods Educ Dept PRIMED, Seremban 70300, Negeri Sembilan, Malaysia
关键词
Atrial fibrillation; dose nomogram; predictors; primary care; TTR; warfarin; INTERNATIONAL NORMALIZED RATIO; PRIMARY-CARE; WARFARIN;
D O I
10.1093/fampra/cmv066
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background. The quality of anticoagulation management in atrial fibrillation patients is reflected by the concept of time spent in therapeutic range (TTR). In a primary care setting, the implementation of a dose nomogram could help increase the mean TTR among these patients. Objective. This study compares the influence of a dose algorithm with an integrated recall on TTR prior to standard care and after the implementation of the protocol. Patients and methods. In a purposive sample of patients with AF, an uncontrolled 'before' and 'after' study design was utilized to measure the effects of the protocol on TTR. Demographic data, TTR levels, frequency of international normalized ratio (INR) within therapeutic range, clinician adherence to dose nomogram and warfarin dose changes were captured from consultations at the anticoagulation clinic. Results. A total of 152 patients with AF were entered into the final analysis. The increment in mean TTR in the 'after' intervention phase (2.9%) was not statistically significant (57.5-60.4%, P = 0.252). The increase in the frequency of INR values within therapeutic range in the 'after' intervention phase was significant (50.0-56.0%, P < 0.05) but with a very low effect size (r = 0.04). Conclusions. The implementation of a dose nomogram has the potential of reducing unnecessary dose changes for minor fluctuations in INR levels. The findings in this study needs to be confirmed in a future study involving other indications for anticoagulation, various regional primary care clinics and a larger population size.
引用
收藏
页码:514 / 519
页数:6
相关论文
共 50 条
  • [31] Novel Therapeutic Targets in the Management of Atrial Fibrillation
    Maan, Abhishek
    Mansour, Moussa
    McManus, David D.
    Patel, Vickas V.
    Cheng, Alan
    Ruskin, Jeremy N.
    Heist, E. Kevin
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2014, 14 (06) : 403 - 421
  • [32] Evaluation of an adaptive, rule-based dosing algorithm to maintain therapeutic anticoagulation during atrial fibrillation ablation
    Kalscheur, Matthew M.
    Martini, Matthew R.
    Mahnke, Marcus
    Osman, Fauzia
    Modaff, Daniel S.
    Fleeman, Blake E.
    Kipp, Ryan T.
    Wright, Jennifer M.
    Medow, Joshua E.
    CARDIOVASCULAR DIGITAL HEALTH JOURNAL, 2023, 4 (06): : 173 - 182
  • [33] CLINICAL PREDICTION MODEL FOR TIME IN THERAPEUTIC RANGE WHILE ON WARFARIN IN NEWLY DIAGNOSED ATRIAL FIBRILLATION
    Williams, Brent
    Evans, Michael
    Honushefsky, Ashley
    Berger, Peter
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 549 - 549
  • [34] Female Sex, Time in Therapeutic Range, and Clinical Outcomes in Atrial Fibrillation Patients Taking Warfarin
    Senoo, Keitaro
    Lip, Gregory Y. H.
    STROKE, 2016, 47 (06) : 1665 - U623
  • [35] TIME IN THERAPEUTIC RANGE PREDICTS MORTALITY AND CEREBROVASCULAR EVENTS IN ATRIAL FIBRILLATION PATIENTS TREATED WITH WARFARIN
    Madhavan, Malini
    Kapa, Suraj
    Roger, Veronique
    Weston, Susan
    Killian, Jill M.
    Asirvatham, Samuel
    Gersh, Bernard
    Chamberlain, Alanna
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 501 - 501
  • [36] PROVIDER INTERPRETATION AND UTILIZATION OF TIME IN THERAPEUTIC RANGE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Brunton, Nichole
    Rouzbehani, Jahangir
    Sostin, Oleg
    Wakefield, Dorothy
    Galin, Ira
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2104 - 2104
  • [37] Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation
    Williams, Brent A.
    Evans, Michael A.
    Honushefsky, Ashley M.
    Berger, Peter B.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (10):
  • [38] Impact of Time in Therapeutic Range on Adverse Events in Atrial Fibrillation Patients in an Ambulatory Care Setting
    Smith, Shannon
    Hogan, Angela R.
    Richow, Wendy
    HOSPITAL PHARMACY, 2024,
  • [39] Effect of Reduced Renal Function on Time in Therapeutic Range Among Anticoagulated Atrial Fibrillation Patients
    Bonde, Anders Nissen
    Lip, Gregory Y. H.
    Kamper, Anne-Lise
    Staerk, Laila
    Torp-Pedersen, Christian
    Gislason, Gunnar Hilmar
    Olesen, Jonas Bjerring
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (06) : 752 - 753
  • [40] Depression as a Driving Force for Low Time in Therapeutic Range and Dementia in Patients With and Without Atrial Fibrillation
    Rizzi, Scott A.
    Knight, Stacey
    May, Heidi T.
    Woller, Scott C.
    Stevens, Scott M.
    Steinberg, Benjamin A.
    Bair, Tami L.
    Anderson, Jeffrey L.
    Muhlestein, Joseph B.
    Knowlton, Kirk U.
    Bunch, T. Jared
    AMERICAN JOURNAL OF CARDIOLOGY, 2021, 153 : 58 - 64